Regulators Target Martin Shkreli Over Alleged Drug Industry Ban Violation
Washington, Tuesday, 13 October 2026.
US regulators asked a court to hold Martin Shkreli in contempt, alleging he violated a lifetime industry ban by trading over 60 drug stocks and promoting investments online.
Contempt Motion Details
On 13 October 2026, the Federal Trade Commission and a coalition of seven U.S. states filed a motion in federal court to hold Martin Shkreli in contempt for allegedly violating a court-mandated lifetime ban from the pharmaceutical industry [1]. The regulatory enforcement action underscores the strict legal exposure faced by corporate executives and investors in heavily regulated sectors who attempt to circumvent antitrust orders and judicial prohibitions [2]. Regulators contend that Shkreli’s activities violate a 2022 court order barring him from the pharmaceutical industry, marking a significant escalation in compliance monitoring [3].
Background on the 2022 Ban
In January 2022, a federal court ordered Shkreli to pay over $64 million and banned him from the drug industry for life following findings that he orchestrated an anti-competitive monopoly for the anti-parasitic drug Daraprim [1]. The lifetime ban stemmed from a separate antitrust case where the FTC and seven states sued Shkreli and other defendants in 2020, alleging that they had used restrictive distribution arrangements to prevent generic-drug developers from competing [3]. The Second Circuit Court of Appeals upheld the ruling in January 2024, solidifying the legal boundaries of his professional conduct [3].
Regulatory Stance and Market Implications
Daniel Guarnera, Director of the FTC’s Bureau of Competition, stated that after a full trial, the court found that Martin Shkreli’s conduct drove up prescription drug costs for American patients and blocked the entry of lower-cost generics [2]. He further emphasized that when judgment is entered by a court, whether it’s a settlement or an order following a trial, defendants must fulfill their obligations [2]. Today’s action should serve as notice that the FTC will not hesitate to enforce violations of court orders [1].